Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Lung cancer in 2014

Optimizing lung cancer treatment approaches

Nature Reviews Clinical Oncology volume 12, pages 75–76 (2015)Cite this article

Subjects

In 2014, developments in our understanding of escape signalling circuits implicated in resistance to targeted agents in patients with lung cancer have led to improvements in tackling such resistance. The potential role for PET in the management of erlotinib therapy, novel combination therapies and pharmacogenomic-driven individualization of platinum-based chemotherapy represent other key advances.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Imbalance in EGFR-mutant signalling networks caused by single-agent TKI therapy.

References

  1. Rosell, R., Bivona, T. G. & Karachaliou, N. Genetics and biomarkers in personalisation of lung cancer treatment. Lancet 382, 720–731 (2013).

    Article  CAS  Google Scholar 

  2. Lee, H. J. et al. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 26, 207–221 (2014).

    Article  CAS  Google Scholar 

  3. Gao, S. P. et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J. Clin. Invest. 117, 3846–3856 (2007).

    Article  CAS  Google Scholar 

  4. Fan, W. et al. MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents. Cancer Res. 71, 4494–4505 (2011).

    Article  CAS  Google Scholar 

  5. Hachemi, M. et al. [18F]FDG positron emission tomography within two weeks of starting erlotinib therapy can predict response in non-small cell lung cancer patients. PLoS ONE 9, e87629 (2014).

    Article  Google Scholar 

  6. Seto, T. et al. Erlotinib alone or with bevacizumab as a first line therapy in patients with advanced non-squamous non-small cell lung cancer harbouring epidermal growth factor receptor mutations (JO25567): a randomised phase II study. Lancet Oncol. 15, 1236–1244 (2014).

    Article  CAS  Google Scholar 

  7. Li, R. et al. Niclosamide overcomes acquired resistance to erlotinib through suppression of STAT3 in non-small cell lung cancer. Mol. Cancer Ther. 12, 2200–2212 (2013).

    Article  CAS  Google Scholar 

  8. Reck, M. et al. Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol. 15, 143–155 (2014).

    Article  CAS  Google Scholar 

  9. Moran, T. et al. Two biomarker-directed randomized trials in European and Chinese patients with non-small-cell lung cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann. Oncol. 25, 2147–2155 (2014).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

Work in the laboratory of R.R. is partially supported by a grant from La Caixa Foundation.

Author information

Authors and Affiliations

  1. Cancer Biology and Precision Medicine Program, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Campus Can Ruti, Carretera Canyet s/n, Badalona, 08916, Barcelona, Spain

    Rafael Rosell

  2. Fundación Molecular Oncology Research (MORe), Quirón Dexeus University Hospital, Sabino Arana 5-19, Barcelona, 08028, Spain

    Niki Karachaliou

Authors
  1. Rafael Rosell
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Niki Karachaliou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Rafael Rosell.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

PowerPoint slides

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rosell, R., Karachaliou, N. Optimizing lung cancer treatment approaches. Nat Rev Clin Oncol 12, 75–76 (2015). https://doi.org/10.1038/nrclinonc.2014.225

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2014.225

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer